Macrae Sandy 4

4 · SANGAMO THERAPEUTICS, INC · Filed Jan 26, 2026

AI-generated summary of this filing

Updated Jan 26, 2026

Sangamo (SGMO) CEO Sandy Macrae Surrenders 102,950 Shares for Taxes

What Happened

Sandy Macrae, President, CEO and Director of Sangamo Therapeutics (SGMO), surrendered 102,950 shares on Jan 22, 2026 to satisfy mandatory tax withholding on vested restricted stock units (RSUs). The filing reports the shares at $0.40 each (closing price used: $0.3985), for a cash value to the company of approximately $41,026. This was a withholding disposition to the issuer (transaction code F), not an open-market sale.

Key Details

Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (timely filing).
Shares surrendered/disposed: 102,950; reported price: $0.40/share (issuer closing price used: $0.3985); total value ≈ $41,026.
Transaction type: F (shares withheld by issuer to cover tax withholding on vested RSUs) — not a discretionary sale.
Footnote F1: Surrender was solely for mandatory tax withholding and is deemed a disposition for reporting; not an open-market trade.
Footnote F2: Notes RSU-related details — e.g., 147,050 shares vested from a Jan 22, 2024 RSU tranche on Jan 22, 2026, plus other RSU grants with future vesting schedules (details in filing). Vesting is subject to continuous service and possible acceleration per the plan.
Shares owned after transaction: not specified in the provided filing excerpt.

Context

This is a routine tax-withholding transaction triggered by RSU vesting. Such surrenders reduce the number of net new shares delivered to the insider but do not reflect a discretionary sale or market sentiment. The dollar amount (~$41k) is modest relative to typical insider trades.

Form 4

Period: 2026-01-22

DirectorPRESIDENT, CEO AND DIRECTOR

Transactions

Tax Payment
Common Stock
[F1][F2]
2026-01-22$0.40/sh−102,950$41,026→ 1,946,584 total

Footnotes (2)

[F1]Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
[F2]Includes: (a) 147,050 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 14,747 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Signature

/s/ Scott Willoughby, Attorney-in-Fact|2026-01-26

1 file